Form 4: Moderna President Stephen Hoge Sells 15,000 Shares Under 10b5-1 Trading Plan

Moderna's President, Stephen Hoge, sold 15,000 shares of common stock at $138.16 per share on June 17, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Stephen Hoge, President of Moderna, Inc., sold 15,000 shares of common stock on June 17, 2024.
• The sale was executed at a price of $138.16 per share.
• The transaction was conducted under a Rule 10b5-1 trading plan adopted on March 15, 2023.
• Following the transaction, Hoge directly owns 1,457,089 shares of Moderna common stock.
• Hoge also indirectly owns 4,116 shares through Valhalla, LLC and 151,933 shares through a trust for the benefit of his spouse and children.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transaction is a routine sale under a pre-arranged trading plan and doesn't necessarily indicate a negative outlook on the company.

Industry Context

Sales by company insiders are a common occurrence and are often pre-planned to avoid accusations of insider trading. The market typically analyzes the frequency, size, and context of such sales to gauge potential impact.

Comparison to Industry Standards

• Executive stock sales are a normal part of corporate compensation.
• Similar sales are seen at companies like Pfizer (PFE) and BioNTech (BNTX), where executives periodically exercise stock options or sell shares for personal financial planning.
• The use of 10b5-1 plans is a standard practice to ensure compliance with insider trading regulations, as seen in filings from other biotech companies such as Amgen (AMGN) and Gilead Sciences (GILD).

Stakeholder Impact

• The sale could have a minor negative impact on shareholder sentiment if perceived negatively, but the pre-planned nature of the sale mitigates this risk.
• The sale does not directly impact employees, customers, suppliers, or creditors.

Key Dates